CA3096101A1 - Amlodipine formulations - Google Patents

Amlodipine formulations Download PDF

Info

Publication number
CA3096101A1
CA3096101A1 CA3096101A CA3096101A CA3096101A1 CA 3096101 A1 CA3096101 A1 CA 3096101A1 CA 3096101 A CA3096101 A CA 3096101A CA 3096101 A CA3096101 A CA 3096101A CA 3096101 A1 CA3096101 A1 CA 3096101A1
Authority
CA
Canada
Prior art keywords
amlodipine
suspension
minutes
benzoate
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3096101A
Other languages
English (en)
French (fr)
Inventor
Scott BRAUER
Gerold L. Mosher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silvergate Pharmaceuticals Inc
Original Assignee
Silvergate Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68161047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3096101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Silvergate Pharmaceuticals Inc filed Critical Silvergate Pharmaceuticals Inc
Publication of CA3096101A1 publication Critical patent/CA3096101A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3096101A 2018-04-11 2019-04-11 Amlodipine formulations Pending CA3096101A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656188P 2018-04-11 2018-04-11
US62/656,188 2018-04-11
PCT/US2019/027044 WO2019200143A1 (en) 2018-04-11 2019-04-11 Amlodipine formulations

Publications (1)

Publication Number Publication Date
CA3096101A1 true CA3096101A1 (en) 2019-10-17

Family

ID=68161047

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3096101A Pending CA3096101A1 (en) 2018-04-11 2019-04-11 Amlodipine formulations

Country Status (6)

Country Link
US (6) US10799453B2 (https=)
EP (1) EP3773574A4 (https=)
JP (1) JP7456933B2 (https=)
CN (1) CN112334134A (https=)
CA (1) CA3096101A1 (https=)
WO (1) WO2019200143A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3960158B1 (en) 2016-10-07 2025-05-21 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
WO2019200143A1 (en) 2018-04-11 2019-10-17 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
CN112716903B (zh) * 2021-01-18 2023-03-21 广州一品红制药有限公司 一种氨氯地平干混悬剂及其制备方法
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US6333342B1 (en) 1998-11-04 2001-12-25 Isotechnika, Inc Methods of pharmacological treatment using S(−) amlodipine
CN1100038C (zh) 2000-02-21 2003-01-29 张喜田 氨氯地平对映体的拆分
PL362660A1 (en) 2000-12-29 2004-11-02 Pfizer Limited Process for making amlodipine maleate
WO2002053540A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Aspartate derivative of amlodipine as calcium channel antagonist
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
EP1309557B9 (en) 2000-12-29 2006-11-15 Pfizer Limited Amlodipine hemimaleate
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
EP1309556B1 (en) 2000-12-29 2004-11-24 Pfizer Limited Amlodipine fumarate
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
CA2433193C (en) 2000-12-29 2006-01-31 Pfizer Limited Amide derivative of amlodipine
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
IL161448A0 (en) 2001-10-24 2004-09-27 Sepracor Inc Method of resolving amlodipine racemate
KR100496436B1 (ko) 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
KR100467669B1 (ko) 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
AU2003253460A1 (en) 2002-09-19 2004-04-08 Cj Corporation Crystalline organic acid salt of amlodipine
CA2559670A1 (en) 2003-04-14 2004-10-28 Gabor Pragai Stable amlodipine maleate formulations
WO2005079772A2 (en) 2004-02-18 2005-09-01 Sepracor Inc. Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
US20060030602A1 (en) * 2004-03-16 2006-02-09 Sepracor Inc. (S)-amlodipine malate
WO2005099699A1 (en) 2004-04-07 2005-10-27 Sepracor Inc. Combination of (s)-amlodipine and a beta-blocker, and methods for reducing hypertension
WO2006059217A1 (en) 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
EP1831166B1 (en) 2004-12-02 2010-10-20 SK Chemicals, Co., Ltd. Optical resolution method of amlodipine
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
CN101522174A (zh) 2006-05-10 2009-09-02 赢创德固赛有限责任公司 辊压热解制备的二氧化硅在药物组合物中的应用
CA2655596C (en) * 2006-06-27 2011-10-25 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
DK2200588T3 (da) 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
CN101416966B (zh) 2007-10-22 2010-11-10 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物
KR20100052262A (ko) 2008-11-10 2010-05-19 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에의해 제조된 분말 및 이를 포함하는 약학적 조성물
CN102256604A (zh) * 2008-12-17 2011-11-23 株式会社医药处方 稳定的氨氯地平含水口服制剂
CN101843615A (zh) 2010-06-25 2010-09-29 包丽昕 含有缬沙坦和苯磺酸氨氯地平的分散片及其制备方法
CN102370965A (zh) 2010-08-11 2012-03-14 南京先宇科技有限公司 一种含有左旋氨氯地平药学上可接受的盐与培哚普利药学上可接受的盐的药物组合物
CN102018708A (zh) 2010-12-12 2011-04-20 林飞 包含氨氯地平和阿托伐他汀镁的药物组合物
CN102114017A (zh) 2011-01-05 2011-07-06 王定豪 包含氨氯地平和培哚普利的药物组合物及其应用
CN102746215A (zh) * 2011-04-18 2012-10-24 张兆勇 一种制备高纯度盐酸贝尼地平的方法
WO2013191668A1 (en) * 2012-06-22 2013-12-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions preventing hypertension comprising soluplus
US20140024723A1 (en) 2012-07-17 2014-01-23 Dow Global Technologies Llc Composition comprising an organic liquid diluent and a specific hydroxypropyl methylcellulose
GB2529605B (en) * 2014-06-03 2018-03-21 Essential Pharmaceuticals Ltd Pharmaceutical composition
EP3960158B1 (en) 2016-10-07 2025-05-21 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
WO2019200143A1 (en) 2018-04-11 2019-10-17 Silvergate Pharmaceuticals, Inc. Amlodipine formulations

Also Published As

Publication number Publication date
US20210308049A1 (en) 2021-10-07
CN112334134A (zh) 2021-02-05
WO2019200143A1 (en) 2019-10-17
US11484498B2 (en) 2022-11-01
US20220401363A1 (en) 2022-12-22
EP3773574A4 (en) 2022-03-02
JP7456933B2 (ja) 2024-03-27
US11918685B2 (en) 2024-03-05
US20230338287A1 (en) 2023-10-26
US20190314279A1 (en) 2019-10-17
US20240252433A1 (en) 2024-08-01
EP3773574A1 (en) 2021-02-17
US12383498B2 (en) 2025-08-12
US20210023003A1 (en) 2021-01-28
US11471409B2 (en) 2022-10-18
JP2021520367A (ja) 2021-08-19
US11701326B2 (en) 2023-07-18
US10799453B2 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
US12336984B2 (en) Amlodipine formulations
US12383498B2 (en) Amlodipine formulations
EP3368012B1 (en) Lisinopril formulations
WO2014055667A1 (en) Enalapril compositions
EP3429581A1 (en) Enalapril formulations

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404